- Faculty Scientist, Division of Cancer Care and Epidemiology, Cancer Research Institute, Queen's University
- Associate Professor and Medical Oncologist, Dept. of Oncology, Queen's University
- Associate Professor, Dept. of Public Health Sciences, Queen's University
- Clinician-Scientist II, Ontario Institute for Cancer Research
- Faculty member, Queen's Global Oncology Program, Queen's University
- Affiliated faculty, Program on Regulation, Therapeutics and Law, Brigham and Women's Hospital, Boston, USA
- Member, WHO Essential Medicine List for Cancer Drugs (2020-)
- ASCO Health Equity and Outcomes Committee (2021-2024)
- ESMO Global Policy Committee (2021-2022)
- ESMO-Magnitude of Clinical Benefit Scale working group (2019-)
- ESMO-MCBS Quality of Life working group (2020-)
- Research consultant, Nepal Health Research Council (2020-)
Bishal Gyawali, MD, PhD is an associate professor in medical oncology and public health sciences, and scientist in the Division of Cancer Care and Epidemiology at Queen’s University, Kingston, Ontario, Canada. He received his medical degree from Nepal, PhD from Japan, research fellowship from Boston and moved to Queen’s University in 2019 as a clinical fellow where he transitioned to Associate Professor in June 2021. Dr. Gyawali’s areas of academic interest include cancer policy, evidence-based oncology, financial toxicities of cancer treatment, clinical trial methods, supportive care, and global oncology. He is an advocate of “cancer groundshot“, a term he coined to imply that investment should be made on proven high-value interventions in cancer care that are easy to implement globally and are affordable. His research works involve health technology assessment impacting approval and funding decisions for cancer drugs, cancer policy including study of the economic consequences of cancer therapies and addressing disparities in cancer care. His research works have helped identify flaws in design of clinical trials that do not benefit patients or lead to misleading conclusions and identify low-value cancer drugs. These are tied to policy issues that help prioritize high-value interventions for patients, and help in shared understanding of risks and benefits of cancer therapeutics. He is passionate about educating patients and advocates, and improving outcomes for patients with cancer all over the globe equitably.
He is part of the editorial and advisory boards of multiple medicine and oncology journals including Cell, JCO Global Oncology, JCO Oncology Practice and ecancer, has authored or co-authored more than a hundred peer-reviewed articles. Dr. Gyawali is the recipient of the 2020 ASCO Conquer Cancer Foundation Global Oncology Young Investigator Award in Implementation Science. He was also awarded by the Government of Nepal with Young Health Researcher Award in 2020.
Dr. Gyawali tweets at @oncology_bg
- Cancer policy
- Regulatory policy
- Health-technology assessment
- Value-based care
- Global oncology
- Disparities in cancer care
- Health services research
- Gyawali B*, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. ESMO Open. 2021 Apr 19;6(3):100117. PMID: 33887690.
- Meyers DE, Jenei K, Chisamore TM, Gyawali B*. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada. JAMA Internal Medicine. 2021. PMID: 33616606.
- Desai A and Gyawali B*. Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions. Eclinicalmedicine, Published by the Lancet. January 31, 2020. PMID: 32300733.
- Gyawali B*, Hey SP, Kesselheim AS. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. JAMA Internal Medicine. 2019. PMID: 31135808.
- Hwang TJ and Gyawali B*. Association between progression-free survival and patients’ quality of life in cancer clinical trials. International Journal of Cancer 2018. PMID: 30374970
For a complete list of publications, please see Dr. Gyawali’s Google Scholar profile.